Boston, MA, May 15, 2018 – Trinity, a leading global life sciences consulting firm, today announced it will attend several important industry events across the U.S. this month. Covering topics ranging from innovation and endocrinology research to managed care, Trinity leaders are looking forward to presenting on and learning the latest updates in rare disease and patient advocacy, health care expenditure and the patient journey to continue to help clients make informed decisions in today’s continuously evolving business landscape.
Life…
Read Now
Boston, MA, April 10, 2018 – Trinity, a leading global life sciences consulting firm, today announced it will participate in eyeforpharma’s 16th Annual Meeting, April 10-11, in Philadelphia, PA.
This year’s eyeforpharma meeting is designed to provide life sciences executives with greater insight into the patient journey. Presenters will highlight strategies to leverage advanced analytics and communication channels and unite organizations around the patient to deliver real value.
“Treatments are becoming more targeted and patients are more involved in the…
Read Now
Rare Disease Day falls on Wednesday, February 28th. At Trinity, we work closely with many life sciences companies developing treatments for rare disease patients. Research is crucial to the rare community, and we are committed to help raise awareness around the importance of medical representation for individuals with rare diseases and their families. Keep an eye on our social media channels this week for some rare disease-focused updates and read on to learn what Rare Disease Day means to Trinity…
Read Now
In a recent article for Managed Healthcare Executive, editor Tracey Walker spoke with Trinity’s Jillian Godfrey Scaife about the findings of Trinity’s recent biosimilar whitepaper. In the article, Jillian highlights key takeaways from the findings. You can read the full story including further insights from Jillian here: http://bit.ly/2Br1FsD…
Read Now
Complex Pricing Structures, Legal and Regulatory Barriers,
and Clinical Uncertainty Hinder Progress in Biosimilar Market Access
Key findings from the report, which seeks to reveal opportunities to accelerate biosimilar adoption, include the following:
Biosimilar pricing to date has not offered the sharp discounts payers expect, after accounting for contract discounts and nuances such as the “rebate trap”;
Biologic innovators have taken legal and promotional actions that derail biosimilar commercial success;
Providers are not fully comfortable with biosimilars and are interested…
Read Now
John Greenaway, Jillian Scaife, Nick Simmons-Stern, Ali Haber, and Christina Danosi are traveling to Alexandria, Virginia this week to attend CBI’s Biosimilars Summit. At the conference, they’ll discuss how to overcome reimbursement hurdles in an expanding U.S. biosimilars market. Learn more about the event here: http://www.cbinet.com/conference/pc18014…
Read Now
Todd Foster, Trinity’s director of advanced analytics, will attend the PMSA’s Multi-Channel Marketing Symposium in Las Vegas, January 18 – 19 2018. During the event, Todd will meet with fellow industry leaders to discuss innovative marketing practices that use data to elevate multi-channel marketing for the biotechnology, medical and pharmaceutical industries. Learn more about the event here: http://bit.ly/2FIL3MS…
Read Now
In a recent article for Managed Healthcare Executive, reporter Mari Edlin spoke with Trinity’s John Corcoran about what he sees in the pipeline for 2018 in terms of drug affordability and pharma’s response to the matter. You can read the full article including further insights from John, here: http://bit.ly/2DHZpwg…
Read Now
In a recent article for Formulary Watch, editor Christine Blank spoke with Trinity’s Leslie Sandberg Orne about new blockbuster drugs to hit the marketplace in 2018 that will treat HIV, diabetes, cancer, migraine headaches and other conditions. Check out Leslie’s insights in the full article, here: http://bit.ly/2ArPeZz…
Read Now
